Novartis selects Microsoft for AI drug development
October 3, 2019Research and Development
Novartis has begun an alliance with Microsoft to leverage the latter’s artificial intelligence (AI) technology for the discovery, development and …
NICE rejects Roche’s immunotherapy Tecentriq in unresectable metastatic triple A breast cancer
October 3, 2019Sales and Marketing Cancer, NICE, Roche, breast cancer, pharma, tecentriq
NICE has revealed its decision not to approve Roche’s immunotherapy Tecentriq (atezolizumab) for use on the NHS in England and …
Government issues first serious shortage protocol to combat lack of the antidepressant fluoxetine
October 3, 2019Manufacturing and Production
The Department of Health and Social care has brought in measures to allow pharmacists to supply alternative strengths of fluoxetine …
Novartis plans FDA approval as it hits endpoint for Consentyx in axial spondyloarthritis
October 3, 2019Research and Development
Novartis has announced positive data from its PREVENT trial, which evaluated the safety and efficacy of Cosentyx (secukinumab) for patients …
Biogen announces leadership updates
October 2, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Biogen have announced updates to it senior leadership team with Alfred Sandrock being named Executive Vice President of Research and …
BMS’ Opdivo bests chemotherapy in oesophageal squamous cell carcinoma
October 2, 2019Research and Development Bristol-Myers Squibb, Cancer, ESMO 2019, opdivo, pharma
Bristol-Myers Squibb took the opportunity at the European Society for Medical Oncology (ESMO) 2019 Annual Congress to present new Phase …
FDA grants Johnson & Johnson’s Invokana new kidney disease approval
October 2, 2019Research and Development
Johnson & Johnson’s Invokana (canaglifolozin) has become the only drug in the SGLT2 inhibitor class to be approved by the …
AstraZeneca strikes global commercial rights deal for $243m
October 2, 2019Research and Development
Cambridge-headquartered AstraZeneca have agreed to sell certain global commercial rights for its Losec brand, in a deal that is worth …
GSK’s Zejula slows disease progression in a range of ovarian cancers
October 2, 2019Research and Development Cancer, ESMO 2019, GSK, Zejula, ovarian cancer, pharma
At the 2019 European Society for Medical Oncology (ESMO) congress, GlaxoSmithKline unveiled new Phase 3 data on Zejula (niraparib) for …
Johnson & Johnson settle opioid lawsuits in Ohio for $20m
October 2, 2019Research and Development
Johnson & Johnson have agreed to settle opioid litigation with two Ohio counties for roughly $20.4 million in a deal …
MSD announce David Peacock as new Managing Director in UK and Ireland
October 1, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
MSD have announced that David Peacock will become Managing Director in the UK and Ireland, succeeding former director Louise Houson, …
Sanofi’s Jevtana doubles progression-free survival in metastatic castration-resistant prostate cancer
October 1, 2019Manufacturing and Production, Research and Development ESMO 2019, Jevtana, Sanofi, pharma, prostate cancer
Sanofi was present at the 2019 European Society of Medical Oncology (ESMO) Congress in Barcelona this year to reveal new …
Chris Whitty begins role as England’s Chief Medical Officer
October 1, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
London consultant and public health professor, Chris Whitty, has begun his role as England’s Chief Medical Officer, taking over from …
Roche’s Tecentriq plus chemo shows promise in first-line, advanced bladder cancer
October 1, 2019Manufacturing and Production, Research and Development Cancer, ESMO 2019, Roche, breast cancer, pharma, tecentriq
Roche has revealed data from an interim analysis of its immunotherapy Tecentriq (atezolizumab) at the 2019 European Society for Medical …
AZ and MSD’s parp inhibitor Lynparza cuts risk of progression and death in prostate cancer
October 1, 2019Manufacturing and Production
AstraZeneca and MSD have shown in their Phase 3 PROfound trial, PARP inhibitor Lynparza (olaparib) reduced the risk of disease …
Sobi to acquire Dova for $915m to broaden hematology franchise
October 1, 2019Manufacturing and Production
Sobi is to buy Dova Pharmaceuticals for $915 million in a bid to grow Sobi’s hematology portfolio, with liver cancer …
ESMO studies show CD4K/6 inhibitor and fulvestrant improves OS in breast cancer
October 1, 2019Manufacturing and Production
Detailed findings from two Phase III trials presented at the European Society for Medical Oncology showed that treatment with a …
Pfizer CEO Albert Bourla to Succeed Ian Read as Executive Chairman
September 30, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Pfizer’s executive chairman Ian Read, is to be succeeded by CEO Albert Bourla with a date to start the post …
The world needs a better plan for cancer survival by 2030
September 30, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Roche, UN General Assembly, United Nations, feature, opinion, pharma
Beginning on 24 September, the UN will convene in New York for its annual General Assermbly. Dr Christian Rommel, Roche´s …
AZ’s Tagrisso extends median overall survival by over 3 years in metastatic, EGFR-mutated lung cancer
September 30, 2019Research and Development, Sales and Marketing AstraZeneca, Cancer, ESMO 2019, Tagrisso, lung cancer, pharma
AstraZeneca took to the stage at the 2019 European Society for Medical Oncology (ESMO) Congress in Barcelona to present new …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
